Active	Status	Sponsor type	Region	Phase	Filter
3 Active 5 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
dexamethasone sodium phosphate-loaded RBC (EDS-EP) / Quince Therap
OLE-IEDAT, NCT03563053 / 2018-000338-36: Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study	Terminated	3	104	Europe, US, RoW	EryDex System	Quince Therapeutics S.p.A.	Ataxia Telangiectasia, Genetic Syndrome	09/22	09/22
NEAT, NCT06193200: Evaluate the Neurological Effects of EryDex on Subjects With A-T	Recruiting	3	106	Europe, US	Dexamethasone sodium phosphate, DSP, Placebo	Quince Therapeutics S.p.A., Biotrial	Ataxia Telangiectasia	08/25	11/25
OLE_NEAT, NCT06664853: Open-Label Extension of EryDex Study IEDAT-04-2022	Recruiting	3	106	Europe, US	Dexamethasone sodium phosphate	Quince Therapeutics S.p.A., Biotrial	Ataxia Telangiectasia	11/26	11/26
erythrocyte-encapsulated therapeutic / Quince Therap
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
dexamethasone sodium phosphate-loaded RBC (EDS-EP) / Quince Therap
OLE-IEDAT, NCT03563053 / 2018-000338-36: Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study	Terminated	3	104	Europe, US, RoW	EryDex System	Quince Therapeutics S.p.A.	Ataxia Telangiectasia, Genetic Syndrome	09/22	09/22
NEAT, NCT06193200: Evaluate the Neurological Effects of EryDex on Subjects With A-T	Recruiting	3	106	Europe, US	Dexamethasone sodium phosphate, DSP, Placebo	Quince Therapeutics S.p.A., Biotrial	Ataxia Telangiectasia	08/25	11/25
OLE_NEAT, NCT06664853: Open-Label Extension of EryDex Study IEDAT-04-2022	Recruiting	3	106	Europe, US	Dexamethasone sodium phosphate	Quince Therapeutics S.p.A., Biotrial	Ataxia Telangiectasia	11/26	11/26
erythrocyte-encapsulated therapeutic / Quince Therap
No trials found